VR Adviser LLC Sells 2,925,769 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

VR Adviser LLC decreased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,629,786 shares of the company's stock after selling 2,925,769 shares during the quarter. Aquestive Therapeutics accounts for about 0.6% of VR Adviser LLC's investment portfolio, making the stock its 25th largest position. VR Adviser LLC owned approximately 2.88% of Aquestive Therapeutics worth $9,362,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $498,000. Harvey Capital Management Inc. lifted its holdings in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after purchasing an additional 249,790 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock valued at $15,474,000 after purchasing an additional 82,958 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Aquestive Therapeutics by 233.6% during the fourth quarter. Renaissance Technologies LLC now owns 95,400 shares of the company's stock valued at $340,000 after purchasing an additional 66,800 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after purchasing an additional 7,347 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Wall Street Analysts Forecast Growth

AQST has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital lowered their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $10.67.

Aquestive Therapeutics Price Performance

Shares of AQST stock traded up $0.06 during mid-day trading on Friday, hitting $2.35. The company had a trading volume of 1,263,613 shares, compared to its average volume of 1,519,334. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The stock's 50 day moving average price is $2.71 and its 200-day moving average price is $3.26. The company has a market capitalization of $233.42 million, a P/E ratio of -5.22 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.